Alex Arfaei

Merck Is Up 40% In 2018: What's Driving The Rally?

BMO Downgrades Pfizer After Q3 Print, Says Risk-Reward 'Fairly Balanced'

BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position

BMO Downgrades Pfizer After Q3 Print, Says Risk-Reward 'Fairly Balanced'

BMO Sees Balanced Risk-Reward In Bristol-Myers, Takes Neutral Position

BMO's Bearish Stance On Eli Lilly Comes To An End

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

BMO's Bearish Stance On Eli Lilly Comes To An End

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Looking For A Better Entry Point, BMO Downgrades Zoetis Shares

Near-Term Events Cast Shadow Of Uncertainty On Bristol-Myers

Alex Arfaei Recent News

Ahead Of Merck's Keytruda PDUFA Date, Analyst Says Expect Approval

Eli Lilly's Guidance Supported By Short-Term Boosts, Not Better Fundamentals

Last Night's Election - A Series Of Fortunate Events For Big Pharma

BMO Capital Upgrades Merck To Outperform, Bullish On Co

BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations

BMO Shows Concern With AbbVie's Major Growth Drivers, Downgrades To Market Perform

BMO Valeant Reaction: 10-K Could Give Investors Confidence To Value Shares Above $60

BMO Still Believes Valeant Is Undervalued

Some On Wall Street Still Back Valeant

BMO Downgrades Whole Foods And Bristol-Myers Squibb To Start Week: Why?

BMO Thinks Valeant's Structure Is 'Questionable,' Says Investigation May Be Needed To Resolve Uncertainty

Calls Of Note: Wall Street Research Moving The Market On Thursday

BMO Downgrades Zoetis After Valeant Report

BMO's Updated Eli Lilly Model Following Earnings

UPDATE: BMO Capital Downgrades Pfizer

UPDATE: BMO Downgrades Bristol-Myers Squibb

UPDATE: BMO Capital Upgrades Eli Lilly

UPDATE: BMO Capital Markets Upgrades Bristol-Myers Squibb on More Positive Outlook

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

UPDATE: BMO Capital Markets Lowers PT on Merck Following New SGLT2 Data